Sugentech Inc (253840) - Total Liabilities

Latest as of March 2026: ₩21.45 Billion KRW ≈ $14.53 Million USD

Based on the latest financial reports, Sugentech Inc (253840) has total liabilities worth ₩21.45 Billion KRW (≈ $14.53 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Sugentech Inc (253840) net asset momentum to track the company's year-over-year net asset growth rate.

Sugentech Inc - Total Liabilities Trend (2017–2025)

This chart illustrates how Sugentech Inc's total liabilities have evolved over time, based on quarterly financial data. See free cash flow generation of Sugentech Inc to measure how efficiently the company converts operating cash flow to free cash.

Sugentech Inc Competitors by Total Liabilities

The table below lists competitors of Sugentech Inc ranked by their total liabilities.

Company Country Total Liabilities
BrilliA Inc
NYSE MKT:BRIA
USA $15.92 Million
Simonds Group Ltd
AU:SIO
Australia AU$151.46 Million
Harbour Energy PLC
LSE:HBR
UK GBX26.15 Billion
Acorn Energy, Inc. Common Stock
NASDAQ:ACFN
USA $4.68 Million
Fiyta Holdings Ltd
SHE:200026
China HK$545.08 Million
WHA Business Complex Freehold and Leasehold Real Estate Investment Trust
BK:WHABT
Thailand ฿564.95 Million
SAMRYOONG Co.Ltd
KQ:014970
Korea ₩41.95 Billion
Yangjisa Co. Ltd
KQ:030960
Korea ₩25.27 Billion

Liability Composition Analysis (2017–2025)

This chart breaks down Sugentech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 253840 company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 10.82 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.30 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.23 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sugentech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sugentech Inc (2017–2025)

The table below shows the annual total liabilities of Sugentech Inc from 2017 to 2025.

Year Total Liabilities Change
2025-12-31 ₩21.67 Billion
≈ $14.68 Million
+106.09%
2024-12-31 ₩10.51 Billion
≈ $7.13 Million
-49.28%
2023-12-31 ₩20.73 Billion
≈ $14.05 Million
-36.64%
2022-12-31 ₩32.72 Billion
≈ $22.17 Million
-40.35%
2021-12-31 ₩54.85 Billion
≈ $37.17 Million
+486.64%
2020-12-31 ₩9.35 Billion
≈ $6.34 Million
-55.71%
2019-12-31 ₩21.11 Billion
≈ $14.31 Million
+136.82%
2018-12-31 ₩8.92 Billion
≈ $6.04 Million
-82.55%
2017-12-31 ₩51.09 Billion
≈ $34.62 Million
--

About Sugentech Inc

KQ:253840 Korea Medical Devices
Market Cap
$40.67 Million
₩60.01 Billion KRW
Market Cap Rank
#22625 Global
#1420 in Korea
Share Price
₩3925.00
Change (1 day)
+3.29%
52-Week Range
₩3620.00 - ₩7860.00
All Time High
₩53604.23
About

Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers lab tests, including systems and test items; and COVID-19 tests. It also provides point of care testing analyzers and test items for testing of influenza A/B, antibody test, COVID-19 and flu, SARS-CoV-2… Read more